Carboxyamidotriazole Complexed to PLGA Is Safe, Effective, and Durable in Models of Neovascular Retinal Disease
Translational Vision Science & Technology · 2025
DOI: 10.1167/tvst.14.3.21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Sergio Li Calzi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Polylactic Acid-Polyglycolic Acid Copolymer, Triazoles, Angiogenesis Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
We evaluated the safety and bioactivity of carboxyamidotriazole (CAI) using two approaches, a polymeric CAI-PLGA nanoemulsion in the mouse model of choroidal neovascularization (CNV) and CAI-loaded bioresorbable intravitreal implant in a rabbit model of vascular leakage.
Methods
Mice underwent laser rupture of Bruch's membrane to induce CNV followed by a single (2 µL volume) intravitreal injection of either vehicle (n = 11); CAI nanoparticles (0.5 µg, 1 µg, 2 µg, 400 nM, 800 nM, and 1.6 µM, respectively); aflibercept 10 µg; or CAI nanoparticles (1 µg) + aflibercept 10 µg. New Zealand white rabbits underwent either sham intravitreal injection, aflibercept 500 µg injection, or CAI-PLGA intravitreal implant. Vascular leakage was induced with injections of VEGF on days 23 and 53. On days 30 and 60, all groups underwent vitreous fluorophotometry and fundus imaging. On day 60, the rabbits were euthanized, and their eyes were enucleated.
Results
Intravitreal injection of the CAI-Nano at the dose of 1 µg significantly decreased choroidal neovascular volume, to 25% of saline on day 7 and 30% on day 14, which was comparable to aflibercept. Vitreous fluorophotometry revealed significantly lower levels of fluorescein in the aflibercept and CAI implant groups compared to the sham group on day 30. On day 60, the CAI implant group showed significantly reduced neovascularization as compared with the aflibercept groups. No toxicity was observed in any group.
Conclusions
CAI in nanoparticle formulation or as a sustained release bioresorbable implant showed potent efficacy and caused no retinal toxicity in murine and rabbit models. Translational Significance: CAI demonstrates strong potential as a sustained release anti-angiogenic therapy with effective long-term durability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Clinical Laboratory and Nutritional Sciences, University of Massachusetts, Lowell, MA, USA.
- ForwardVue Pharma, Mobile, AL, USA.
Förderung
- NEI NIH HHS
Zitieren
APA
Li Calzi, S., Fujihashi, A., Chakraborty, D., Adu-Rutledge, Y., Prasad, R., Ready, E. L. V., Paul, S., Kakumanu, S., Qi, X., Boulton, M. E., Franklin, A. J., Katz, B. H., & Grant, M. B. (2025). Carboxyamidotriazole Complexed to PLGA Is Safe, Effective, and Durable in Models of Neovascular Retinal Disease. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.3.21
Vancouver
Li Calzi S, Fujihashi A, Chakraborty D, Adu-Rutledge Y, Prasad R, Ready ELV, et al. Carboxyamidotriazole Complexed to PLGA Is Safe, Effective, and Durable in Models of Neovascular Retinal Disease. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.3.21
BibTeX
@article{LiCalzi2025,
author = {Li Calzi, Sergio and Fujihashi, Ayaka and Chakraborty, Dibyendu and Adu-Rutledge, Yvonne and Prasad, Ram and Ready, Edgar L V and Paul, Sarbodeep and Kakumanu, Srikanth and Qi, Xiaoping and Boulton, Michael E and Franklin, Alan J and Katz, Bob H and Grant, Maria B},
title = {Carboxyamidotriazole Complexed to PLGA Is Safe, Effective, and Durable in Models of Neovascular Retinal Disease},
journal = {Translational Vision Science & Technology},
year = {2025},
doi = {10.1167/tvst.14.3.21}
}
EUVIMED